Trial Profile

A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adavosertib (Primary) ; Durvalumab
Indications Advanced breast cancer; Colon cancer; Lung cancer; Solid tumours
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

25 Feb 2025 Planned End Date changed from 29 Dec 2023 to 31 Dec 2025.
24 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
25 Nov 2022 Planned End Date changed from 19 Dec 2022 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com